• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

透析患者的血管通路类型及相关临床结局

Types of Vascular Access and Associated Clinical Outcomes in Dialysis Patients.

作者信息

Nenova Diana D, Yankov Yanko G

机构信息

Second Department of Internal Disease, Medical University "Prof. Dr. Paraskev Stoyanov", Varna, BGR.

Clinic of Nephrology and Dialysis, University Hospital "St. Marina", Varna, BGR.

出版信息

Cureus. 2025 May 7;17(5):e83691. doi: 10.7759/cureus.83691. eCollection 2025 May.

DOI:10.7759/cureus.83691
PMID:40486410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12144399/
Abstract

Background Vascular access in patients with end-stage renal disease (ESRD) plays a crucial role in determining both the quality of life and survival rates, as it directly affects dialysis effectiveness. It connects the patient to the dialysis machine and significantly impacts the dialysis dose by influencing blood flow efficiency. Despite advancements in technology, improved care, and collaborative efforts by healthcare providers and patients, complications related to vascular access continue to be a major cause of hospitalizations and mortality among patients with ESRD. Our study aims to evaluate how vascular access impacts the dialysis dose and clinical outcomes, with the ultimate target of enhancing patients' quality of life while minimizing costs to the healthcare system. We seek to identify new strategies to reduce complications associated with vascular access, which contribute to inadequate dialysis and higher mortality rates, and to encourage the integration of these strategies into routine clinical practice. Methodology This retrospective study was conducted at the Clinic of Nephrology and Dialysis at the University Hospital "St. Marina" in Varna, Bulgaria, over five years, from January 2017 to December 2021. During this period, the medical records and routine laboratory tests of 87 patients who met the study criteria were reviewed. Patients were categorized into two groups based on the type of permanent vascular access: Group 1 included 45 patients with an arteriovenous fistula (AVF), and Group 2 included 42 patients with a permanent tunneled vascular catheter (PC). During the study period, the specified indicators, along with recorded mortality and hospitalization rates, were analyzed in relation to the type of vascular access. Results Our analysis demonstrated the significant superiority of AVF in several key areas. Specifically, patients with AVF showed significantly higher dialysis adequacy, as measured by the single-pool Kt/V index (spKt/V) and urea reduction ratio (URR), along with higher serum hemoglobin levels and lower erythropoietin requirements (< 0.0001). The results of our study showed that using PC as vascular access is associated with a significantly higher risk of death, four times greater than in patients with AVF (< 0.0001). The significantly higher incidence of complications in the PC is well-researched and is directly linked to an increased rate of hospitalizations and mortality in this group. These outcomes are primarily due to access-related events, but also reflect the broader impact of compromised dialysis adequacy. Inadequate dialysis, in turn, worsens clinical outcomes, potentiating issues such as malnutrition, chronic inflammation, and immune dysfunction. These factors collectively contribute to the poor prognosis observed in patients with PC, reinforcing the importance of optimal vascular access in improving patient survival and quality of life. Conclusions In conclusion, although indwelling tunneled catheters may be necessary in certain situations, our findings confirm the superior outcomes associated with the use of AVF in terms of dialysis adequacy, survival, anemia control, and overall quality of life, data supported by two large multicenter trials on this topic. AVF placement must be prioritized whenever possible to reduce complications and improve the long-term prognosis of patients with ESRD.

摘要

背景

终末期肾病(ESRD)患者的血管通路对于决定生活质量和生存率起着至关重要的作用,因为它直接影响透析效果。它将患者与透析机相连,并通过影响血流效率显著影响透析剂量。尽管技术有所进步、护理得到改善,且医疗服务提供者和患者共同努力,但与血管通路相关的并发症仍然是ESRD患者住院和死亡的主要原因。我们的研究旨在评估血管通路如何影响透析剂量和临床结果,最终目标是提高患者生活质量,同时将医疗系统成本降至最低。我们试图确定新的策略以减少与血管通路相关的并发症,这些并发症会导致透析不充分和死亡率升高,并鼓励将这些策略纳入常规临床实践。

方法

这项回顾性研究于2017年1月至2021年12月在保加利亚瓦尔纳“圣玛丽娜”大学医院肾脏病与透析诊所进行,为期五年。在此期间,对87名符合研究标准的患者的病历和常规实验室检查进行了回顾。根据永久性血管通路的类型将患者分为两组:第1组包括45名动静脉内瘘(AVF)患者,第2组包括42名永久性带隧道中心静脉导管(PC)患者。在研究期间,分析了特定指标以及记录的死亡率和住院率与血管通路类型的关系。

结果

我们的分析表明,AVF在几个关键领域具有显著优势。具体而言,通过单池Kt/V指数(spKt/V)和尿素清除率(URR)衡量,AVF患者的透析充分性显著更高,同时血清血红蛋白水平更高,促红细胞生成素需求更低(<0.0001)。我们的研究结果表明,使用PC作为血管通路与死亡风险显著更高相关,比AVF患者高四倍(<0.0001)。PC中并发症的显著更高发生率已得到充分研究,并且与该组住院率和死亡率的增加直接相关。这些结果主要归因于与通路相关的事件,但也反映了透析充分性受损的更广泛影响。透析不充分反过来会恶化临床结果,加剧营养不良、慢性炎症和免疫功能障碍等问题。这些因素共同导致了PC患者预后不良,强化了最佳血管通路在改善患者生存和生活质量方面的重要性。

结论

总之,尽管在某些情况下留置带隧道导管可能是必要的,但我们的研究结果证实,在透析充分性、生存率、贫血控制和总体生活质量方面,使用AVF具有更好的结果,两项关于该主题的大型多中心试验支持了这些数据。只要有可能,必须优先进行AVF置管,以减少并发症并改善ESRD患者的长期预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645d/12144399/5cd157e0b9fa/cureus-0017-00000083691-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645d/12144399/f906fec5e746/cureus-0017-00000083691-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645d/12144399/0c397808bc46/cureus-0017-00000083691-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645d/12144399/5cd157e0b9fa/cureus-0017-00000083691-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645d/12144399/f906fec5e746/cureus-0017-00000083691-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645d/12144399/0c397808bc46/cureus-0017-00000083691-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645d/12144399/5cd157e0b9fa/cureus-0017-00000083691-i03.jpg

相似文献

1
Types of Vascular Access and Associated Clinical Outcomes in Dialysis Patients.透析患者的血管通路类型及相关临床结局
Cureus. 2025 May 7;17(5):e83691. doi: 10.7759/cureus.83691. eCollection 2025 May.
2
Nonstandardized High-Intensity Dialysis Dose Improves Survival in Patients With End-Stage Renal Disease.非标准化高强度透析剂量可提高终末期肾病患者的生存率。
Cureus. 2024 Oct 17;16(10):e71725. doi: 10.7759/cureus.71725. eCollection 2024 Oct.
3
Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study.血管通路的使用情况及结果:来自透析预后与实践模式研究的国际视角
Nephrol Dial Transplant. 2008 Oct;23(10):3219-26. doi: 10.1093/ndt/gfn261. Epub 2008 May 29.
4
Comparison of Complications of Arteriovenous Fistula with Permanent Catheter in Hemodialysis Patients: A Six-month Follow-up.血液透析患者动静脉内瘘与永久性导管并发症的比较:六个月随访
Adv Biomed Res. 2017 Aug 28;6:106. doi: 10.4103/2277-9175.213666. eCollection 2017.
5
Hemodialysis血液透析
6
Vascular Access Type and Survival Outcomes in Hemodialysis Patients: A Seven-Year Cohort Study.血液透析患者的血管通路类型与生存结局:一项七年队列研究。
Medicina (Kaunas). 2025 Mar 25;61(4):584. doi: 10.3390/medicina61040584.
7
Gender differences in vascular access in hemodialysis patients in the United States: developing strategies for improving access outcome.美国血液透析患者血管通路的性别差异:制定改善通路结局的策略
Gend Med. 2007 Sep;4(3):193-204. doi: 10.1016/s1550-8579(07)80040-4.
8
Access type as a predictor of dialysis adequacy in chronic hemodialysis patients.通路类型作为慢性血液透析患者透析充分性的预测指标
ASAIO J. 2000 May-Jun;46(3):279-82. doi: 10.1097/00002480-200005000-00007.
9
CMS ESRD quality incentive program has not improved patient dialysis vascular access.CMS ESRD 质量激励计划并未改善患者透析血管通路。
J Vasc Access. 2023 Mar;24(2):246-252. doi: 10.1177/11297298211027054. Epub 2021 Jul 5.
10
Patients started on hemodialysis with tunneled dialysis catheter have similar survival after arteriovenous fistula and arteriovenous graft creation.开始使用带隧道的透析导管进行血液透析的患者,在动静脉内瘘和动静脉移植物建立后的生存率相似。
J Vasc Surg. 2015 Dec;62(6):1590-7.e2. doi: 10.1016/j.jvs.2015.07.076. Epub 2015 Sep 12.

本文引用的文献

1
Risk Factor Analysis in Vascular Access Complications for Hemodialysis Patients.血液透析患者血管通路并发症的危险因素分析
Diagnostics (Basel). 2025 Jan 2;15(1):88. doi: 10.3390/diagnostics15010088.
2
Endovascular intravascular intervention for central venous stenosis in maintenance hemodialysis patients: a retrospective observational study.维持性血液透析患者中心静脉狭窄的血管内介入治疗:一项回顾性观察研究。
Front Cardiovasc Med. 2024 Dec 9;11:1405606. doi: 10.3389/fcvm.2024.1405606. eCollection 2024.
3
Characteristics of Vascular Access Cannulation Complications in End Stage Kidney Disease Patients in West Java from 2018 to 2022: A Retrospective Observational Study.
2018年至2022年西爪哇末期肾病患者血管通路插管并发症的特征:一项回顾性观察研究
Int J Nephrol Renovasc Dis. 2024 Feb 12;17:47-58. doi: 10.2147/IJNRD.S440467. eCollection 2024.
4
Multiple single cannulation technique of arteriovenous fistula: A randomized controlled trial.动静脉瘘管的多次单腔插管技术:一项随机对照试验。
Hemodial Int. 2022 Jan;26(1):4-12. doi: 10.1111/hdi.12962. Epub 2021 Jul 6.
5
New Devices and Technologies for Hemodialysis Vascular Access: A Review.新的血液透析血管通路设备和技术:综述。
Am J Kidney Dis. 2021 Jul;78(1):116-124. doi: 10.1053/j.ajkd.2020.11.027. Epub 2021 May 6.
6
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.KDIGO 临床实践指南:血管通路 2019 更新版。
Am J Kidney Dis. 2020 Apr;75(4 Suppl 2):S1-S164. doi: 10.1053/j.ajkd.2019.12.001. Epub 2020 Mar 12.
7
Percutaneous treatment of vascular access-site complications: a ten years' experience in two centres.经皮治疗血管穿刺部位并发症:两个中心的十年经验
CVIR Endovasc. 2020 Jun 8;3(1):29. doi: 10.1186/s42155-020-00120-7.
8
US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States.美国肾脏数据系统2019年年报:美国肾脏疾病流行病学
Am J Kidney Dis. 2020 Jan;75(1 Suppl 1):A6-A7. doi: 10.1053/j.ajkd.2019.09.003. Epub 2019 Nov 5.
9
Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study.经皮隧道式血液透析导管相关并发症:加拿大观察性队列研究。
Am J Kidney Dis. 2019 Apr;73(4):467-475. doi: 10.1053/j.ajkd.2018.10.014. Epub 2019 Jan 12.
10
Comparison of tunneled central venous catheters and native arteriovenous fistulae by evaluating the mortality and morbidity of patients with prevalent hemodialysis.比较隧道式中心静脉导管和原生动静脉瘘在评估现有血液透析患者死亡率和发病率方面的作用。
J Formos Med Assoc. 2019 Apr;118(4):807-814. doi: 10.1016/j.jfma.2018.08.025. Epub 2018 Sep 21.